ONCOLYTICS BIOTECH INC — Form 8-K
Filed October 14, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Oncolytics completed enrollment in its GOBLET Phase 1/2 study evaluating pelareorep combined with checkpoint inhibitors across gastrointestinal cancers. The company will receive final PanCAN grant payment this quarter following Cohort 5 completion. Final Cohort 4 results (pelareorep + atezolizumab in anal cancer) expected Q4 2026; initial Cohort 5 results (pelareorep-based therapy in pancreatic cancer) expected H1 2027. All enrolled cohorts met pre-specified efficacy success criteria; Cohort 4 median overall survival exceeded expectations.
Why this rating
Clinical trial completion and imminent data readouts are material milestones for $72M biotech. Multiple positive interim signals (all cohorts met efficacy criteria, Cohort 4 OS exceeded expectations) reduce downside risk. Data timing provides near-term catalysts. Moderate uncertainty remains on final efficacy levels and regulatory path.
See more from October 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.